Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;First, heavy! Shanghai merger and reorganization action plan announcedXinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.
Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;After the market closed, the Shanghai Municipal Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027). Among them, it is proposed to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan. In addition, the plan also mentioned that the merger of securities companies should be accelerated to build a first-class investment bank.This "moderately loose" statement the day before yesterday is definitely a major positive. Yesterday, A shares opened higher and went lower, but it was still expected to be too full! The high pressure level of 3500 was superimposed, so it dropped sharply. After-hours, the national society issued a document to interpret "moderate easing", and everyone understands the signal! This is a kind of expected management, which embodies the intention of caring for the economy and the stock market.
Let's talk about some encouraging and unintelligent observations. Now the main purpose of everyone's smashing is to adjust positions, not to sell them back. This is the biggest difference from the past few years! Explain that regardless of retail investors, institutions and foreign investors, they still believe in the A-share bull market.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Recently, all localities are vigorously promoting mergers and acquisitions, first in Shenzhen and then in Shanghai, and it is estimated that Beijing will soon. The listed companies in the north and Shenzhen are all active, and the merger of Shanghai benchmark brokerage Haitong+Guotai Junan has landed! Other places will follow suit, but mergers and acquisitions are really difficult to grasp, and it is estimated that there are more local+state-owned assets.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide
12-13